Can Denmark’s world-beating drugs maker stay ahead?
Thanks to its weight loss drug, Novo Nordisk briefly became Europe’s most valuable firm in 2023.
Similar Posts
All eyes are on glaucoma, the ‘silent thief of sight’ — and the truth behind 7 myths
To kick off Glaucoma Awareness Month in January, experts are setting the record straight on some common myths about what the American Academy of Ophthalmology (AAO) calls the “silent thief of sight.” Approximately three million Americans have glaucoma. Yet only half of them are aware they have the potentially blinding disease, according to the Centers…
6 Stupid Holiday Food ‘Rules’ That Are Really Diets In Disguise
It’s the most wonderful time of the year ― unless you’re on a diet and have set impossible standards for eating during the holidays. There’s nothing wrong with taking an “everything in moderation” approach at the dinner table, but other “rules” we establish for ourselves around the holidays can actually hinder rather than help our…
Most patients using weight-loss drugs like Wegovy stop within a year, data show | Reuters News Agency
Health 11 July 2023, 5:39 pm 1 minute Reuters exclusively reported that Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk’s (NOVOb.CO) Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply. Market Impact Shares of the Danish drugmaker fell 2.3% on Tuesday. Article…
New COVID variant JN.1 now comprises up to 30% of US cases: CDC
The latest variant of the COVID-19 virus, JN.1, is now responsible for an estimated 15% to 29% of cases in the U.S. as of Dec. 8, according to a posted update from the Centers for Disease Control and Prevention (CDC). JN.1, which is currently the country’s fastest growing variant, is expected to continue to increase…
Asia’s year in review: Who had it good — and who had it bad — in 2023
Curtis S. Chin, a former U.S. ambassador to the Asian Development Bank, is managing director of advisory firm RiverPeak Group. Jose B. Collazo is an analyst focusing on the Indo-Pacific region. Follow them on X at @CurtisSChin and @JoseBCollazo. As 2023 comes to a close, we take a look at the year that was in…
How some Indian hospitals are cutting cancer drug costs
Baby Nandi, 58, is waiting for her next chemotherapy session at the Cachar hospital clinic. Previously, she had to travel 2,000km (1,242 miles) for breast cancer treatment. The drugs alone cost $650 for one treatment cycle. She needed six cycles. Along with the travel and accommodation costs, her family’s finances were pushed to the brink.
